Novo Nordisk A/S: Arthritis, Rheumatoid trials
The registry lists 13 Arthritis, Rheumatoid studies with Novo Nordisk A/S as lead sponsor. 0 are open to participants now and 0 have results posted.
Phase 1 7Phase 2 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to MethotrexateWithdrawnNCT02097264Phase 2
- A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid ArthritisCompletedNCT01955603Phase 1
- A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid ArthritisCompletedNCT01647451Phase 2
- A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to MethotrexateTerminatedNCT01636843Phase 2
- A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa BiologicsTerminatedNCT01636817Phase 2
- First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid ArthritisCompletedNCT01611688Phase 1
- Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid ArthritisCompletedNCT01565408Phase 1
- Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis PatientsTerminatedNCT01559103Phase 1
- Efficacy of NNC109-0012 in Subjects With Active Rheumatoid ArthritisCompletedNCT01282255Phase 2
- A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid ArthritisCompletedNCT01223911Phase 2
- First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid ArthritisCompletedNCT01208506Phase 1
- Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid ArthritisCompletedNCT01038674Phase 1
- Safety and Tolerability of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid ArthritisCompletedNCT00818064Phase 1